SPATA21 Inhibitors
Chemical inhibitors of SPATA21 function through diverse mechanisms to disrupt its activity within cells. Trichostatin A and Bortezomib, function by modulating the stability and modification state of proteins. Trichostatin A, a histone deacetylase inhibitor, can change the acetylation state of histones linked with SPATA21, potentially altering chromatin structure and reducing gene accessibility for transcription. Bortezomib, like MG132, inhibits the proteasome system, which is responsible for protein degradation. This inhibition can lead to the accumulation of regulatory proteins that interact with SPATA21, thereby inhibiting its function. MG132, in a similar vein, may prevent the degradation of SPATA21 regulatory proteins, allowing them to inhibit SPATA21 activity by stabilizing inactive complexes or influencing signaling pathways.
In addition to these, LY294002 and Wortmannin, both PI3K inhibitors, can disrupt downstream signaling pathways that regulate SPATA21. By inhibiting PI3K, these chemicals can alter the localization or post-translational modifications of SPATA21, leading to functional inhibition. Rapamycin, an mTOR inhibitor, works further downstream by affecting protein synthesis pathways that can regulate SPATA21. SB203580 and SP600125 target MAPK pathways, with SB203580 inhibiting p38 MAPK and SP600125 targeting JNK, both of which can influence SPATA21 activity indirectly through stress-activated and apoptosis signaling pathways. PD98059 and U0126, both inhibitors of the MEK pathway, prevent the activation of ERK, which can also regulate SPATA21. Lastly, KN-93 and PP2 target kinase signaling, with KN-93 inhibiting CaMKII and PP2 inhibiting Src family kinases, both of which can affect the activity of SPATA21 through various signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Given that histone acetylation status can impact chromatin structure and gene expression, this chemical may inhibit SPATA21 by altering the acetylation state of histones associated with the SPATA21 gene, leading to changes in chromatin structure that result in reduced accessibility of the gene to the transcriptional machinery. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor. By inhibiting the proteasome, this chemical could prevent the degradation of regulatory proteins that, when stabilized, inhibit the function of SPATA21 by either sequestering it in an inactive complex or by modulating signaling pathways that control SPATA21 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling can regulate a variety of cellular functions, including those related to the activity of proteins like SPATA21. Inhibition of PI3K can lead to downstream effects that inhibit SPATA21 function, possibly through alterations in cellular localization or post-translational modifications. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in cellular stress responses and its inhibition can affect the activity of proteins that are regulated by stress-activated pathways, potentially including SPATA21, through indirect mechanisms that lead to functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK signaling pathway. By inhibiting MEK, this chemical can inhibit the phosphorylation of ERK and consequently alter the activity of downstream proteins that might regulate the activity of SPATA21, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor with a mechanism of action similar to LY294002. By inhibiting PI3K, it can affect downstream signaling pathways that are potentially involved in regulating SPATA21 activity, leading to its inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor like MG132. It can inhibit the degradation of proteins that regulate the function of SPATA21, leading to the accumulation of such regulatory proteins and the subsequent inhibition of SPATA21. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it can affect downstream signaling pathways and protein synthesis that are potentially involved in the regulation of SPATA21 activity, thereby functionally inhibiting SPATA21. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, similar to PD98059. By inhibiting these MEK enzymes, U0126 can prevent the activation of ERK, which may be involved in signaling pathways that regulate SPATA21 activity, thereby leading to its functional inhibition. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is an inhibitor of CaMKII (calcium/calmodulin-dependent protein kinase II). CaMKII is involved in calcium signaling pathways, and by inhibiting this kinase, KN-93 can affect signaling pathways that may regulate SPATA21 activity, leading to functional inhibition. | ||||||